SCHEMBL19911477

SCHEMBL19911477

Cc1ccc2c(c1)nnn2S(C)(=O)=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.49
KCNMA1 Q12791 2/20 0.47
TSHR P16473 4/20 0.41
KMT2A Q03164 3/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 5/20 0.40
GAA P10253 4/20 0.40
ALDH1A1 P00352 3/20 0.39
USP2 O75604 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 1/20 0.37
MEN1 O00255 2/20 0.36
MGAM O43451 1/20 0.36
AMY1A P0DUB6 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
POLB P06746 2/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848206 0.86 SLC9A1 (0.49) SLC9A1KCNMA1TSHRKMT2AHSD17B10
SCHEMBL9800298 0.85 SLC9A1 (0.48) SLC9A1KCNMA1TSHRKMT2AHSD17B10
SCHEMBL19911593 0.81 L3MBTL1 (0.47) SLC9A1TSHRKMT2AHSD17B10ALDH1A1
SCHEMBL19848323 0.81 KDM4E (0.48) SLC9A1KCNMA1TSHRKMT2AHSD17B10
SCHEMBL19848576 0.80 SLC9A1 (0.69) SLC9A1KCNMA1TSHRKMT2AHSD17B10
SCHEMBL19911506 0.79 L3MBTL1 (0.56) TSHRKMT2AHSD17B10LMNAGAA
SCHEMBL19911448 0.79 GAA (0.46) SLC9A1TSHRKMT2AHSD17B10GAA
SCHEMBL19915878 0.78 PKM (0.56) SLC9A1KCNMA1TSHRKMT2AHSD17B10
SCHEMBL19848568 0.78 ALDH1A1 (0.38) SLC9A1TSHRKMT2AHSD17B10GAA
SCHEMBL19911487 0.77 SLC9A1 (0.42) SLC9A1KCNMA1TSHRKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 SLC9A1 341/4885KCNMA1 525/4885TSHR 2034/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SLC9A1 341/4885KCNMA1 525/4885TSHR 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.